These are the sodium-glucose cotransporter-2 inhibitors (SGLT2i) used in diabetes treatment, the statins for dyslipidemia and the naturally cardio-protective omega-3 fatty acids (Omega-3 FA). This evidence concerns the gene SLC5A2 and diabetes mellitus.